Comparative study of oral and parenteral administration of sho-saiko-to (xiao-chaihu-tang) extract on D-galactosamine-induced liver injury in rats.
The preventive effect of Sho-saiko-to (Xiao-Chaihu-Tang) extract (TJ-9) on the progression of D-galactosamine (GaIN)-induced liver injury was examined in five week-old male Wistar rats with oral (p.o.) or intraperitoneal (i.p.) administration of the same dose of TJ-9. Rats treated once with GaIN (500 mg/kg body weight, i.p.) received TJ-9 at a dose of 1.0 g/kg body weight (p.o. or i.p.) 2 hours after GaIN treatment at which time an apparent liver injury occurred. Both p.o. and i.p. administration of TJ-9 showed similar significant prevention against the progression of liver injury 24 hours after GaIN injection. Although total protein and albumin concentrations in serum and protein concentration in the liver decreased with the progression of GaIN-induced liver injury, oral or i.p. administration of TJ-9 prevented these decreases in similar degree. However, decreases in serum and liver triglyceride concentration with the progression of liver injury were not attenuated after p.o. or i.p. administration of TJ-9. The activities of liver 5'-nucleotidase and glucose-6-phosphatase, marker enzymes of liver plasma and microsomal membranes, respectively, decreased during the progression of liver injury. A similar preventive effect on the decrease of both enzyme activities was found after p.o. or i.p. administration of TJ-9. These results indicate that the preventive effect on progression of GaIN-induced liver injury by oral or i.p. administration is approximately equal, and that the effect may be through improving the impaired liver protein synthesis and disrupted liver plasma and microsomal membranes in a similar degree.
Ohta
Y
Y
Department of Biochemistry, School of Medicine, Fujita Health University, Aichi, Japan.
Nishida
K
K
Sasaki
E
E
Kongo
M
M
Hayashi
T
T
Nagata
M
M
Ishiguro
I
I
D015720:5'-Nucleotidase / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D015415:Biomarkers / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000494:pharmacology*; D005688:Galactosamine; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008107:Liver Diseases / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D015415:Biomarkers; D004365:Drugs, Chinese Herbal; D000960:Hypolipidemic Agents; D012709:Serum Albumin; D014280:Triglycerides; C018142:saiko-keishi-to; D005688:Galactosamine; D015720:5'-Nucleotidase; D005952:Glucose-6-Phosphatase